{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:10:08Z","timestamp":1759050608248,"version":"3.44.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013865","name":"Stiftung Charit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jneuroim.2020.577469","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T01:48:58Z","timestamp":1608860938000},"page":"577469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis \u2013 A report of two cases"],"prefix":"10.1016","volume":"351","author":[{"given":"Frauke","family":"Stascheit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linna","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Baum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2020.577469_bb0005","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2020.577469_bb0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12020-017-1289-2","article-title":"Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab","volume":"58","author":"Brilli","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.jneuroim.2020.577469_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7010018","article-title":"Daclizumab: mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis","volume":"7","author":"Cohan","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.jneuroim.2020.577469_bb0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bulcan.2020.01.012","article-title":"Checkpoint inhibitors-induced hypophysitis","volume":"107","author":"du Payrat","year":"2020","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.jneuroim.2020.577469_bb0025","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","article-title":"Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis","volume":"373","author":"Kappos","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2020.577469_bb0030","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1212\/NXI.0000000000000481","article-title":"GFAPalpha IgG-associated encephalitis upon daclizumab treatment of MS","volume":"5","author":"Luessi","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2020.577469_bb0035","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1212\/NXI.0000000000000481","article-title":"GFAP\u03b1 IgG-associated encephalitis upon daclizumab treatment of MS","volume":"5","author":"Luessi","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2020.577469_bb0040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archneurol.2009.16","article-title":"Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis","volume":"66","author":"Oh","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2020.577469_bb0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2020.577469_bb0050","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005854","article-title":"Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy","volume":"91","author":"Rauer","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2020.577469_bb0055","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1212\/NXI.0000000000000479","article-title":"Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS","volume":"5","author":"Scheibe","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2020.577469_bb0060","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1212\/NXI.0000000000000539","article-title":"A fatal case of daclizumab-induced liver failure in a patient with MS","volume":"6","author":"Stettner","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2020.577469_bb0065","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1177\/1352458518819098","article-title":"Severe meningo\u2212\/encephalitis after daclizumab therapy for multiple sclerosis","volume":"25","author":"Stork","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2020.577469_bb0070","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneurol.2013.95","article-title":"Modulation of IL-2R\u03b1 with daclizumab for treatment of multiple sclerosis","volume":"9","author":"Wiendl","year":"2013","journal-title":"Nat. Rev. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282030730X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282030730X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:37:54Z","timestamp":1759048674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557282030730X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":14,"alternative-id":["S016557282030730X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577469","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis \u2013 A report of two cases","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577469"}}